JP2017508442A5 - - Google Patents

Download PDF

Info

Publication number
JP2017508442A5
JP2017508442A5 JP2016546862A JP2016546862A JP2017508442A5 JP 2017508442 A5 JP2017508442 A5 JP 2017508442A5 JP 2016546862 A JP2016546862 A JP 2016546862A JP 2016546862 A JP2016546862 A JP 2016546862A JP 2017508442 A5 JP2017508442 A5 JP 2017508442A5
Authority
JP
Japan
Prior art keywords
genes listed
derivative
mdm2i
salt
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016546862A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017508442A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2015/051157 external-priority patent/WO2015108175A1/en
Publication of JP2017508442A publication Critical patent/JP2017508442A/ja
Publication of JP2017508442A5 publication Critical patent/JP2017508442A5/ja
Pending legal-status Critical Current

Links

JP2016546862A 2014-01-14 2015-01-13 Mdm2阻害剤に対する感受性と関連する遺伝子シグネチャー Pending JP2017508442A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461927310P 2014-01-14 2014-01-14
US61/927,310 2014-01-14
PCT/JP2015/051157 WO2015108175A1 (en) 2014-01-14 2015-01-13 Gene signatures associated with sensitivity to mdm2 inhibitors

Publications (2)

Publication Number Publication Date
JP2017508442A JP2017508442A (ja) 2017-03-30
JP2017508442A5 true JP2017508442A5 (enExample) 2018-02-08

Family

ID=52432889

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016546862A Pending JP2017508442A (ja) 2014-01-14 2015-01-13 Mdm2阻害剤に対する感受性と関連する遺伝子シグネチャー

Country Status (4)

Country Link
US (1) US20160333419A1 (enExample)
EP (1) EP3094746A1 (enExample)
JP (1) JP2017508442A (enExample)
WO (1) WO2015108175A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
CN108929375A (zh) 2011-10-18 2018-12-04 爱勒让治疗公司 拟肽大环化合物
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CN104812384B (zh) 2012-11-01 2020-09-18 爱勒让治疗公司 二取代的氨基酸及其制备和使用方法
MX389354B (es) 2014-09-24 2025-03-20 Aileron Therapeutics Inc Macrociclos peptidomimeticos y formulaciones de los mismos.
JP2017533889A (ja) 2014-09-24 2017-11-16 エルロン・セラピューティクス・インコーポレイテッドAileron Therapeutics,Inc. ペプチド模倣大環状分子およびその使用
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
TWI804010B (zh) * 2015-08-03 2023-06-01 瑞士商諾華公司 作為血液學毒性生物標記之gdf-15
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
JP2018538247A (ja) 2015-10-23 2018-12-27 第一三共株式会社 Amlを処置することに用いるための医薬組成物およびそれを必要とする対象においてamlを処置する方法
JP6855472B2 (ja) 2015-10-23 2021-04-07 第一三共株式会社 がんを治療するためのmdm2阻害剤の投与計画
CN106512009B (zh) * 2016-10-28 2019-10-11 武汉大学 Ph同源域家族a成员3(phlda3)在治疗心肌肥厚中的应用
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
WO2020235671A1 (ja) * 2019-05-23 2020-11-26 国立大学法人大阪大学 性ホルモン非感受性greb1陽性腫瘍の治療剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE045880T2 (hu) * 2012-07-31 2020-01-28 Novartis Ag A humán double minute 2 (MDM2) inhibitorra való érzékenységgel összefüggõ markerek
CA2912547A1 (en) * 2013-07-03 2015-01-08 F. Hoffmann-La Roche Ag Mrna-based gene expression for personalizing patient cancer therapy with an mdm2 antagonist

Similar Documents

Publication Publication Date Title
JP2017508442A5 (enExample)
CN112930569B (zh) 无细胞dna中的微卫星不稳定性检测
Degtyareva et al. Regulatory SNPs: altered transcription factor binding sites implicated in complex traits and diseases
Tuaeva et al. Translational application of circulating DNA in oncology: review of the last decades achievements
Schlauch et al. Genome-wide association analysis identifies genetic variations in subjects with myalgic encephalomyelitis/chronic fatigue syndrome
Desai et al. Next‐generation sequencing: ready for the clinics?
JP2013127477A5 (enExample)
Bonnefond et al. Highly sensitive diagnosis of 43 monogenic forms of diabetes or obesity through one-step PCR-based enrichment in combination with next-generation sequencing
EP4574992A3 (en) Combinatorial dna screening
JP2017523810A5 (enExample)
Lin et al. Identification of latent biomarkers in hepatocellular carcinoma by ultra-deep whole-transcriptome sequencing
Vos et al. Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial
Noviello et al. Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial
Vasli et al. Impacts of massively parallel sequencing for genetic diagnosis of neuromuscular disorders
JP2017512491A5 (enExample)
JP2016000057A5 (enExample)
JP2012501452A5 (enExample)
JP2017532959A5 (enExample)
Millat et al. Evaluation of a new high-throughput next-generation sequencing method based on a custom AmpliSeq™ library and ion torrent PGM™ sequencing for the rapid detection of genetic variations in long QT syndrome
JP2011528903A5 (enExample)
JP2025026905A (ja) ヒト腫瘍のがん細胞における分子活性を定量化するための方法
JP2017509351A5 (enExample)
Caberlotto et al. Systems biology meets-omic technologies: novel approaches to biomarker discovery and companion diagnostic development
RU2009127735A (ru) Определение предрасположенности к раку путем идентификации генотипических комбинаций специфичных вариантов генов cyp1b1, brca2 и снек2
JP2012120540A5 (ja) 遺伝子発現プロファイルによる胃癌の検出